<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353869</url>
  </required_header>
  <id_info>
    <org_study_id>GLUTADIAB</org_study_id>
    <nct_id>NCT04353869</nct_id>
  </id_info>
  <brief_title>Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications</brief_title>
  <acronym>GLUTADIAB</acronym>
  <official_title>Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Agency, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental data suggest that glutamine catabolism in involved in the activation of&#xD;
      macrophages by generating TCA(Tricarboxylic acid) intermediates that promote the&#xD;
      pro-inflammatory polarization of macrophages. The project investigates the possible link&#xD;
      between glutaminolysis, monocytes polarization and diabetes related cardiovascular&#xD;
      complications in humans&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate the role of glutamine metabolism in the&#xD;
      pro-inflammatory activation of macrophages in diabetes and related cardiovascular&#xD;
      complications.&#xD;
&#xD;
      The study focuses on 5 adult patients' population with different diabetic status and level of&#xD;
      cardiovascular risk:&#xD;
&#xD;
        -  Patients with uncomplicated type 1 or type 2 diabetes and low cardiovascular risk&#xD;
&#xD;
        -  Patients with uncomplicated type 1 or type 2 diabetes and high cardiovascular risk&#xD;
&#xD;
        -  Patients with complicated type 1 or type 2 diabetes&#xD;
&#xD;
        -  Patients without diabetes and with a high cardiovascular risk&#xD;
&#xD;
        -  Patients without diabetes and with a history of cardiovascular event&#xD;
&#xD;
      Participants (n=1650) will be recruited at clinical sites, in the diabetes and cardiology&#xD;
      departments (APHP, Bichat - Claude-Bernard Hospital and APHP, Lariboisière Hospital), over a&#xD;
      2-year period.&#xD;
&#xD;
      The study will consist in a single visit. During a scheduled hospitalization or consultation&#xD;
      as part of the follow-up of their diabetes or as part of the follow-up of their cardiological&#xD;
      problems, clinical data will be collected as well as additional blood and urine samples for&#xD;
      analyses and biobanking. There will be no other intervention specific to the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.</measure>
    <time_frame>DAY 1</time_frame>
    <description>plasma concentration of glutamine in each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study glutamine metabolism in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>plasma concentration of glutamate in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study glutamine metabolism in patients with various levels of CV risk</measure>
    <time_frame>DAY1</time_frame>
    <description>plasma concentration of a-ketoglutarate, fumarate, and succinate in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study glutamine metabolism in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>monocyte cytoplasmic concentration of a-ketoglutarate, fumarate and succinate in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study the inflammatory status in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>plasma concentration of VEGF (Vascular endothelial growth factor) in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study the inflammatory status in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>plasma concentration of the proinflammatory cytokines IL-1, IL-6, IL-8 (interleukin) and TNF-a (Tumor Necrosis Factor alpha)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study the inflammatory status in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>blood concentration of circulating PBMCs (peripheral blood mononuclear cell)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study the monocyte activation status in patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>frequency of monocyte subsets (CD14++CD16+, CD14++CD16++, CD14+CD16++)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B (Lysine Demethylase 6B) and TET2 (Ten-eleven-translocation 2) activity in blood monocytes from patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>Number of transcript for each gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>Number of methylated gene loci and their proportion of methylation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk</measure>
    <time_frame>DAY 1</time_frame>
    <description>Frequency and level of histone H3K27me (Methylation of lysine 27 on histone H3) methylation</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1650</enrollment>
  <condition>Glutamine</condition>
  <condition>Diabetic</condition>
  <condition>Cardiovascular Complications</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with uncomplicated diabetes and low cardiovascular risk&#xD;
During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:&#xD;
A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients with uncomplicated diabetes and high cardiovascular risk&#xD;
During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:&#xD;
A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients with complicated diabetes&#xD;
During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:&#xD;
A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Patients without diabetes and with a high cardiovascular risk&#xD;
Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:&#xD;
A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Patients without diabetes and with a history of cardiovascular event&#xD;
Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:&#xD;
A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bio collection</intervention_name>
    <description>venous blood sampling and collection of urine</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood, Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Type 1 and 2 diabetic patients and non-diabetic subjects with various levels of&#xD;
        cardiovascular risk&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria General inclusion criteria applying to the five populations are the&#xD;
        following:&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  BMI between 25 and 40 kg/m²&#xD;
&#xD;
        Inclusion criteria according to study group are listed below.&#xD;
&#xD;
        Group 1: Patients with uncomplicated diabetes and low cardiovascular risk, additional&#xD;
        inclusion criteria are:&#xD;
&#xD;
          -  5 or more years of diabetes&#xD;
&#xD;
          -  6% &lt; HbA1c &lt; 9%&#xD;
&#xD;
          -  No history of cardiovascular event, diabetic microvascular complications (normal&#xD;
             kidney function and albuminuria/creatininuria &lt; 30 mg/g) except background of&#xD;
             non-proliferative moderate retinopathy&#xD;
&#xD;
          -  Coronary artery calcium score &lt; 100 (assessment &lt; 12 months)&#xD;
&#xD;
        Group 2: Patients with uncomplicated diabetes and high cardiovascular risk, additional&#xD;
        inclusion criteria are:&#xD;
&#xD;
          -  5 or more years of diabetes&#xD;
&#xD;
          -  6% &lt; HbA1c &lt; 9%&#xD;
&#xD;
          -  No history of cardiovascular event, diabetic microvascular complications (normal&#xD;
             kidney function and albuminuria/creatininuria &lt; 30 mg/g) except background of&#xD;
             non-proliferative moderate retinopathy.&#xD;
&#xD;
          -  Coronary artery calcium score &gt; 400 (assessment &lt; 12 months)&#xD;
&#xD;
        Group 3: Patients with complicated diabetes, additional inclusion criteria are:&#xD;
&#xD;
          -  5 or more years of diabetes&#xD;
&#xD;
          -  6% &lt; HbA1c &lt; 9%&#xD;
&#xD;
          -  A history of cardiovascular event (myocardial infarction, stroke, peripheral vascular&#xD;
             disease, or angioplasty) at least 3 months ago&#xD;
&#xD;
        Group 4: Patients without diabetes and with a high cardiovascular risk, additional&#xD;
        inclusion criteria are:&#xD;
&#xD;
          -  Fasting glycemia &lt; 1,26 g/l&#xD;
&#xD;
          -  No history of cardiovascular event (myocardial infarction, stroke, peripheral vascular&#xD;
             disease, or angioplasty)&#xD;
&#xD;
          -  A coronary artery calcium score &gt;400, (assessment &lt; 12 months)&#xD;
&#xD;
        Group 5: Patients without diabetes and with a history of cardiovascular event, additional&#xD;
        inclusion criteria are:&#xD;
&#xD;
          -  Fasting glycemia &lt; 1,26 g/l&#xD;
&#xD;
          -  A history of cardiovascular event (myocardial infarction, stroke, peripheral vascular&#xD;
             disease, or angioplasty) at least 3 months ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Solid organ or bone marrow transplant patient&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Absence of free and informed consent&#xD;
&#xD;
          -  Non-affiliation to a social security regimen or CMU (universal health coverage)&#xD;
&#xD;
          -  Subject deprived of freedom, subject under a legal protective measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronan ROUSSEL, MD, PhD</last_name>
    <phone>01 40 25 65 47</phone>
    <phone_ext>33</phone_ext>
    <email>ronan.roussel@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline DECHANET</last_name>
    <phone>01 40 25 78 30</phone>
    <email>aline.dechanet@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiologie Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Henry, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetologie Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François GAUTIER, MD, PhD</last_name>
      <phone>01 49 95 90 20</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabétologie - Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois GAUTIER</last_name>
      <phone>01 49 95 90 20</phone>
      <email>jean-francois.gautier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiologie Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel STEG, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Cardiovascular complications</keyword>
  <keyword>Glutamine metabolism</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

